Published in MD Week, September 7th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Amgen.
Report 1: Amgen (NASDAQ:AMGN) today submitted testimony for the record of the House Ways & Means Subcommittee on Health hearing on "Ensuring Kidney Patients Receive Safe and Appropriate Anemia Management Care."
Amgen cited data in its testimony showing that the majority of EPOGEN(R) (Epoetin alfa) use in dialysis has been and continues to be appropriate. When examined over time, 83 percent of patient hemoglobin excursions above 12 g/dL fall below 12 g/dL within three...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of MD Week